David C. Hastings

Insider Reports History

Entity
Individual
Location
C/O Arbutus Biopharma, 100 8900 Glenlyon Parkway, Burnaby, British Columbia, Canada
Signature
/s/ Robert F. Joyce Jr., by Power of Attorney
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by David C. Hastings:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Arbutus Biopharma Corp Chief Financial Officer Common Shares 182K $421K $2.31 Feb 2, 2024 Direct
SCYNEXIS INC Director Common Stock 46.2K $75.3K $1.63 Jun 20, 2024 Direct
Arbutus Biopharma Corp Chief Financial Officer Stock Option (Right to Buy) 450K Feb 1, 2024 Direct
SCYNEXIS INC Director Stock Option 23K Jun 20, 2024 Direct
Entasis Therapeutics Holdings Inc. Director Common Stock 0 $2.20 Jul 11, 2022 Direct
Entasis Therapeutics Holdings Inc. Director Stock Option (right to buy) 0 Jul 11, 2022 Direct

Insider Reports Filed by David C. Hastings

Symbol Company Period Transactions Value $ Form Type Date Filed Role
SCYX SCYNEXIS INC Jun 20, 2024 2 $0 4 Jun 21, 2024 Director
ABUS Arbutus Biopharma Corp Feb 1, 2024 3 -$22.2K 4 Feb 5, 2024 Chief Financial Officer
SCYX SCYNEXIS INC Jun 15, 2023 1 $0 4 Jun 23, 2023 Director
SCYX SCYNEXIS INC Jun 15, 2023 1 $0 4 Jun 20, 2023 Director
ABUS Arbutus Biopharma Corp Feb 1, 2023 2 $0 4 Feb 3, 2023 Chief Financial Officer
VBLT Vascular Biogenics Ltd. Jan 1, 2023 0 $0 3 Jan 3, 2023 Director
ETTX Entasis Therapeutics Holdings Inc. Jul 7, 2022 4 -$109K 4 Jul 11, 2022 Director
SCYX SCYNEXIS INC Jun 17, 2022 2 $0 4 Jun 22, 2022 Director
ABUS Arbutus Biopharma Corp Jan 20, 2022 1 $801K 4 Jan 20, 2022 Chief Financial Officer
ETTX Entasis Therapeutics Holdings Inc. Jan 18, 2022 1 $0 4 Jan 19, 2022 Director
ETTX Entasis Therapeutics Holdings Inc. Jul 16, 2021 6 $0 4 Feb 15, 2022 Director
SCYX SCYNEXIS INC Jun 16, 2021 1 $0 4 Jun 21, 2021 Director